These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957 [TBL] [Abstract][Full Text] [Related]
5. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766 [TBL] [Abstract][Full Text] [Related]
6. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222 [TBL] [Abstract][Full Text] [Related]
7. Ipilimumab-induced hypophysitis, a single academic center experience. Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112 [TBL] [Abstract][Full Text] [Related]
8. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769 [TBL] [Abstract][Full Text] [Related]
12. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265 [TBL] [Abstract][Full Text] [Related]
14. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386 [TBL] [Abstract][Full Text] [Related]
15. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411 [TBL] [Abstract][Full Text] [Related]
16. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943 [TBL] [Abstract][Full Text] [Related]
17. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Daly LE; Power DG; O'Reilly Á; Donnellan P; Cushen SJ; O'Sullivan K; Twomey M; Woodlock DP; Redmond HP; Ryan AM Br J Cancer; 2017 Jan; 116(3):310-317. PubMed ID: 28072766 [TBL] [Abstract][Full Text] [Related]